Company news
Scynexis, Inc. news in 2020
Scynexis, Inc.'s news releases, calls and decks from 2020, newest first.
SCYNEXIS Announces Closing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
December 21, 2020
SCYNEXIS Announces Pricing of $85 Million Public Offering of Common Stock, Pre-Funded Warrants and Warrants
December 16, 2020
SCYNEXIS Announces Launch of $50 Million Public Offering of Common Stock and Warrants
December 15, 2020
SCYNEXIS Announces Advancement of Ibrexafungerp’s Intravenous Formulation to Clinical Stage and Provides Further Updates on its Clinical Studies in Patients with Life-Threatening Fungal Infections
December 9, 2020
SCYNEXIS Announces FDA Acceptance and Priority Review of New Drug Application for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infections
December 6, 2020
SCYNEXIS Reports Third Quarter 2020 Financial Results and Provides Company Update
November 5, 2020
SCYNEXIS Announces Submission of New Drug Application to the U.S. Food and Drug Administration for Oral Ibrexafungerp for the Treatment of Vaginal Yeast Infection
October 13, 2020
SCYNEXIS to Present Two Posters Highlighting Ibrexafungerp for the Treatment of Vaginal Yeast Infection at the 23rd Annual Premier Women's Healthcare Virtual Conference
October 11, 2020
SCYNEXIS Announces Presentations at 2020 IDSOG Virtual Annual Meeting Highlighting Ibrexafungerp’s Potential for the Treatment of Vulvovaginal Candidiasis
August 12, 2020
SCYNEXIS Reports Second Quarter 2020 Financial Results and Provides Company Update
August 9, 2020
SCYNEXIS Reports Successful Completion of Pre-NDA Meetings with the FDA Regarding Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis
July 28, 2020
SCYNEXIS Announces Four Posters Presented at ASM Microbe 2020 Highlighting the Potential Clinical Utility of Ibrexafungerp
July 21, 2020
SCYNEXIS Announces One-for-Ten Reverse Stock Split
July 15, 2020
SCYNEXIS Strengthens Leadership Team with Appointment of Jim Maffezzoli as Vice President of Marketing and Sales
June 1, 2020
SCYNEXIS Reports First Quarter 2020 Financial Results and Provides Company Update
May 10, 2020
SCYNEXIS Announces Six Abstracts Published by 30th ECCMID Highlighting the Potential Clinical Utility of Ibrexafungerp
May 5, 2020
SCYNEXIS Announces Positive Top-Line Results from its Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
April 20, 2020
SCYNEXIS and Aspire Capital Enter into $20 Million Common Stock Purchase Agreement
April 12, 2020
SCYNEXIS Secures $10 Million in Financing through Senior Convertible Note Purchase Agreement with Puissance Capital
April 8, 2020
SCYNEXIS Reports Full Year 2019 Financial Results and Provides Company Update
March 10, 2020
SCYNEXIS Announces Preclinical Data on Ibrexafungerp and Azoles against Aspergillus Presented at the 9th Advances Against Aspergillosis and Mucormycosis Conference
March 4, 2020
SCYNEXIS Completes Patient Enrollment Ahead of Schedule in the Second Pivotal Phase 3 Study (VANISH-306) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (Vaginal Yeast Infection)
February 12, 2020
SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
January 7, 2020